DAILY LEAD
A predictive 14-gene signature and FLI1 inhibition overcome tumor-infiltrating lymphocyte dysfunction in triple-negative breast cancer.
Observation and source date: 23 July 2026. This edition uses PubMed Date-Publication records; the matching arXiv submitted-date window returned no relevant new records.
Transcriptomics, network analysis and machine learning on TILs from nine TNBC patients produced a 14-gene reactivity signature and nominated FLI1 as an intervention node.
The cohort is very small, and pharmacological rescue in experimental models is not yet a patient-selection or treatment result.